Alan P Skarbnik

Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial

Jeff P. Sharman, Miklós Egyed, Wojciech Jurczak et al. · The Lancet · 2020 · 583 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Oncology +8

Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis

Anthony R. Mato, Chadhi Nabhan, Meghan C. Thompson et al. · Haematologica · 2018 · 439 citations · Full text

The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

Ian W. Flinn, Peter Hillmen, Marco Montillo et al. · Blood · 2018 · 331 citations · Full text

The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients

Steven P. Treon, Jorge J. Castillo, Alan P Skarbnik et al. · Blood · 2020 · 327 citations · Full text

Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients

Anthony R. Mato, Brian T. Hill, Nicole Lamanna et al. · Annals of Oncology · 2017 · 219 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Optimal Sequencing +11